Duvelisib dosage and usage

The dosage and usage of Duvelisib (Duvelisib) should be determined according to the patient's disease type, clinical status and doctor's prescription. The following are general dosage guidelines:

1. Tcell lymphoma:

The recommended initial dose for adultsTcell leukemia lymphoma (ATLL) and lymphoma cell leukemia (CTCL) is usually 25 mg daily.

The dose can be taken orally once a day, preferably at the same time as a meal or 2 hours after a meal.

Initial dose adjustments and subsequent treatment doses may be individualized based on patient response and adverse effects.

2. SmallB cell lymphoma:

The recommended initial dose for relapsed smallBcell lymphoma, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), is usually 25mg daily.

The dose can be taken orally once a day, preferably at the same time as a meal or 2 hours after a meal.

Initial dose adjustments and subsequent treatment doses may be individualized based on patient response and adverse effects.

Patients need to closely follow their doctor's advice while taking duvelisel and take the medication accurately as prescribed. Physicians may periodically evaluate the patient's disease status and drug response and make dosage adjustments as necessary. Patients should avoid adjusting dosage or interrupting treatment unless directed by their physician. Adverse reactions such as infection, diarrhea, skin reactions, etc. need to be reported to the doctor in time so that appropriate management measures can be taken.

The original drug of Duvelisel Capsules has been launched in China, but it is not covered by medical insurance. Patients can buy it domestically at a price of more than 20,000 yuan. For specific prices, please consult the local hospital pharmacy.